ArticleJournal of global antimicrobial resistance2024
Genomic resistant determinants of multidrug-resistant Campylobacter spp. isolates in Peru.
Article in Journal of global antimicrobial resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 21 citations in OpenAlex.
- Enhancing surveillance of foodborne bacteria and antimicrobial resistance using a large centralized laboratory database: Case study of Campylobacter and nontyphoidal Salmonella in Peru.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026Article
- Robust performance of culture, real-time PCR, and genomic approaches for shigella serotyping in a pediatric surveillance cohort.PLoS neglected tropical diseases · 2026Article
- Protocols for genomic epidemiology and source attribution of enteric bacteria causing diarrhoeal disease across Africa.BMJ open · 2026Article
- Identification of a core set ofMicrobiology (Reading, England) · 2026Article
- Phenotypic Resistance of Ciprofloxacin and Azithromycin ResistantbioRxiv : the preprint server for biology · 2026Article
- Article
- Robust Performance of Culture, qPCR, and Genomic Approaches for Shigella Serotyping in a Pediatric Surveillance Cohort.medRxiv : the preprint server for health sciences · 2026Article
- Tetracyclines in the Modern Era: Global Consumption, Antimicrobial Resistance, Environmental Occurrence, and Degradation Techniques.Antibiotics (Basel, Switzerland) · 2025Review
- Pangenomic Characterization ofPathogens (Basel, Switzerland) · 2025Article
- Strain sharing and mobile genetic elements shape the interconnected resistomes of Campylobacter coli in Brazil.BMC biology · 2025Article
- Prevalence, antibiotic resistance, resistance and virulence determinants ofOne health (Amsterdam, Netherlands) · 2025Review
- Article
- Sharing ofmBio · 2025Article
- Mutation-based mechanism and evolution of the potent multidrug efflux pump RE-CmeABC inProceedings of the National Academy of Sciences of the United States of America · 2024Article
- New Campylobacter Lineages in New Zealand Freshwater: Pathogenesis and Public Health Implications.Environmental microbiology · 2024Article
- Machine learning to attribute the source of Campylobacter infections in the United States: A retrospective analysis of national surveillance data.The Journal of infection · 2024Article
- Genotypic characterization and antimicrobial susceptibility of humanMicrobiology spectrum · 2024Article
- Harnessing medicinal plant compounds for the control of Campylobacter in foods: a comprehensive review.Veterinary research communications · 2024Review
- Occurrence of Florfenicol and Linezolid Resistance and Emergence ofInternational journal of microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 8 institutions in 3 countries.
Funding
Abstract
objectivesAntimicrobial resistant (AMR) Campylobacter is a global health threat; however, there is limited information on genomic determinants of resistance in low- and middle-income countries. We evaluated genomic determinants of AMR using a collection of whole genome sequenced Campylobacter jejuni and C. coli isolates from Iquitos, Peru.
methodsCampylobacter isolates from two paediatric cohort studies enriched with isolates that demonstrated resistance to ciprofloxacin and azithromycin were sequenced and mined for AMR determinants.
resultsThe gyrA mutation leading to the Thr86Ile amino acid change was the only gyrA mutation associated with fluoroquinolone resistance identified. The A2075G mutation in 23S rRNA was present, but three other 23S rRNA mutations previously associated with macrolide resistance were not identified. A resistant-enhancing variant of the cmeABC efflux pump genotype (RE-cmeABC) was identified in 36.1% (35/97) of C. jejuni genomes and 17.9% (12/67) of C. coli genomes. Mutations identified in the CmeR-binding site, an inverted repeat sequence in the cmeABC promoter region that increases expression of the operon, were identified in 24/97 C. jejuni and 14/67 C. coli genomes. The presence of these variants, in addition to RE-cmeABC, was noted in 18 of the 24 C. jejuni and 9 of the 14 C. coli genomes.
conclusionsBoth RE-cmeABC and mutations in the CmeR-binding site were strongly associated with the MDR phenotype in C. jejuni and C. coli. This is the first report of RE-cmeABC in Peru and suggests it is a major driver of resistance to the principal therapies used to treat human campylobacteriosis in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.